Evidence map›Paper›PMID 41907095›Full record

ArticleCellular and molecular bioengineering2026

FGF-2-Overexpressing Adipose-Derived Stem Cells as a Paracrine Platform for Angiogenesis-Driven Tissue Regeneration.

Daisuke Seki, Michiyo Honda

Erratum issuedAbstract read
In one paragraph

Article in Cellular and molecular bioengineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Daisuke SekiDepartment of Applied Chemistry, School of Science and Technology, Meiji University, 1-1-1 Higashimita, Tama-ku, Kawasaki, Kanagawa 214-8571 Japan.
Michiyo HondaDepartment of Applied Chemistry, School of Science and Technology, Meiji University, 1-1-1 Higashimita, Tama-ku, Kawasaki, Kanagawa 214-8571 Japan.ORCID 0000-0002-7611-4798

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The survival and function of three-dimensional tissues critically depend on the establishment of a functional vascular network that ensures oxygen and nutrient supply and waste removal. Insufficient vascularization leads to hypoxia, metabolic stress, and cell death, making angiogenesis a fundamental requirement for successful tissue regeneration. This requirement is particularly evident in highly vascularized tissues such as bone, where vascular networks closely regulate tissue metabolism and repair. Methods: Human adipose-derived mesenchymal stem cells (ASCs) were genetically modified to overexpress fibroblast growth factor 2 (FGF-2), a key regulator of angiogenesis. The angiogenic potential of these cells and the paracrine effects of their conditioned medium were subsequently evaluated, together with their effects on osteogenic differentiation to assess functional specificity. Results: Overexpression of FGF-2 in ASCs enhanced endothelial cell migration and tube formation via paracrine mechanisms, in which elevated secretion of VEGFA and other angiogenic factors acted synergistically to promote angiogenesis. In contrast, osteogenic differentiation of ASCs was significantly inhibited by FGF-2 overexpression. Notably, Conclusion: Our results demonstrate that FGF-2-overexpressing ASCs function not as osteogenic effector cells but as a potent paracrine platform for angiogenesis. Their conditioned medium, enriched with FGF-2 and synergistic angiogenic factors, supports vascular network formation and indirectly enhances the regenerative microenvironment, highlighting its potential as a cell-free strategy for tissue regeneration.

Indexed as

Adipose-derived mesenchymal stem cellsAngiogenesisFGF-2OsteogenesisParacrine signal

Identifiers

PMID41907095
PMCPMC13031578

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.